Opere olmuş kolon kanseri hastalarında tümörlü dokuda adiponektin ekspresyonunun prognostik değeri
Date
2011
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Uludağ Üniversitesi
Abstract
Adiponektinin obezite ile ilişkili malignitelerin oluşumu ve progresyonunda anahtar rol oynayabileceğini düşündüren yayınlar vardır. Etiyolojik bir faktör olarak değerlendirilen adiponektinin opere kolon tümörlü hastalarda prognostik değeri araştırıldı.Merkezimizde 1997-2007 yılları arasında kolon kanseri nedeni ile opere edilmiş evre II ve III 53 hastanın parafin bloklarında İmmünohistokimyasal olarak adiponektin ekspresyonu ve prognoz üzerine olan etkileri değerlendirildi.Olguların 32'si (%60.4) erkek, 21'i (%39.6) kadın olup ortalama yaşı 58.3±10.1 (35- 78). Olguların ortalama takip süresi 41 ay (10 - 96 ay) idi. TNM sınıflamasına göre olguların 28'inin (%52.8) evre II ve 25'inin (%47.2) evre III olduğu belirlendi. İmmünohistokimyasal inceleme sonucunda 21 (%39.6) vakada tümör dokusunda adiponektin ile boyanma izlendi. Boyanmalar sitoplazmik olarak görüldü. Adiponektin ekspresyonunun olduğu 21 vakadan 9'unda (%42.9) nüks gelişirken, ekspresyonu olmayan 32 vakadan 11'inde (%34.4) nüks gözlendi. Ortalama HSK adiponektin ekspresyonu varlığında 60.3±9.03 ay iken yokluğunda 68.7±6.67 ay olarak hesaplandı (p:0.414).Epidemiyolojik çalışmalarda düşük adiponektin seviyelerinin meme, endometriyum, prostat ve kolorektal kanserlerde artmış risk ile ilişkisi gösterilmiştir. Adiponektin etkilerini hem kanser hücrelerini direkt etkileyerek hem de tüm vücutta insülin duyarlığını etkileyerek dolaylı olarak gösterir. Tümör dokusunda adiponektin ekspresyonun HSK üzerinde olumsuz etkisi gösterilse de ek çalışmalar ile desteklenmesi gerekmektedir.
Some of the trials suggesting that adiponectin may play a key role in the genesis and progression of the obesity-related malignancies. The prognostic value of adiponectin, that assessing as an etiological factor, was evaluated on operated colon cancer patients.53 paraffin blocks of patients who have been operated for stage II/III colon cancer, were investigated with immunhistochemistry for adiponectin expression and the effects on prognosis.32 patients (60.4%) males and 21 (39.6%) were female, mean age 58.3 ± 10.1 (35 - 78). The median follow-up period was 41 months (10-96 months). According to TNM classification 28 (%52.8) cases were stage II, 25 (47.2%) cases were stage III. In immunohistochemical examination, 21 (39.6 %) patients were observed staining with adiponectin. The staining was seen as cytoplasmic. 9 of the 21(42.9%) patients with adiponectin expression had recurrence, 11 of the 32 (34.4%) with no adiponectin expression had recurrence. The mean DFS was 60.3 ± 9.03 months for patients who had adiponectin expression, and 68.7 ± 6.67 months for patients who had no adiponectin expression (p=0.414).In epidemiological studies showed that the association with low serum adiponectin levels and increased the risk in breast, endometrial, prostate and colorectal cancers. Adiponectin may act directly on cancer cells or indirectly by regulating whole-body insulin sensitivity. Tumor tissue adiponectin expression may indicate adverse outcomes on DFS, but this data should be supported with additional studies.
Some of the trials suggesting that adiponectin may play a key role in the genesis and progression of the obesity-related malignancies. The prognostic value of adiponectin, that assessing as an etiological factor, was evaluated on operated colon cancer patients.53 paraffin blocks of patients who have been operated for stage II/III colon cancer, were investigated with immunhistochemistry for adiponectin expression and the effects on prognosis.32 patients (60.4%) males and 21 (39.6%) were female, mean age 58.3 ± 10.1 (35 - 78). The median follow-up period was 41 months (10-96 months). According to TNM classification 28 (%52.8) cases were stage II, 25 (47.2%) cases were stage III. In immunohistochemical examination, 21 (39.6 %) patients were observed staining with adiponectin. The staining was seen as cytoplasmic. 9 of the 21(42.9%) patients with adiponectin expression had recurrence, 11 of the 32 (34.4%) with no adiponectin expression had recurrence. The mean DFS was 60.3 ± 9.03 months for patients who had adiponectin expression, and 68.7 ± 6.67 months for patients who had no adiponectin expression (p=0.414).In epidemiological studies showed that the association with low serum adiponectin levels and increased the risk in breast, endometrial, prostate and colorectal cancers. Adiponectin may act directly on cancer cells or indirectly by regulating whole-body insulin sensitivity. Tumor tissue adiponectin expression may indicate adverse outcomes on DFS, but this data should be supported with additional studies.
Description
Keywords
Adiponektin, Kolon kanseri, Obezite ilişkili maligniteler, Adiponectin, Colon cancer, Obesity-related malignancies
Citation
Canhoroz, M. (2011). Opere olmuş kolon kanseri hastalarında tümörlü dokuda adiponektin ekspresyonunun prognostik değeri. Yayınlanmamış uzmanlık tezi. Uludağ Üniversitesi Tıp Fakültesi.